Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems - an observational cohort study.

What Was Tested

This clinical trial looks at Vitamin D, K2, Magnesium and Zinc.

Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters.

Why It Was Studied

Polyunsaturated fatty acids are essential nutrients for humans.

They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids.

Who Took Part

The study group was 810 children.

By PubMed's age tags, the people studied were young children, children and teenagers, both men and women.

The food supplement ESPRICO® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc.

Assessment was performed by internationally standardised evaluation scales, i.e.

How the Study Was Run

Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented.

What Was Measured

The subject headings attached to it are Affective Symptoms, Attention, Attention Deficit Disorder with Hyperactivity, Cohort Studies, Dietary Supplements, Fatty Acids, Omega-3 and Fatty Acids, Omega-6.

What This Means in Plain Language

This is a clinical trial of Vitamin D, K2, Magnesium and Zinc in 810 children.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Lipids in health and disease), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.